23 Jun BioCity, Glasgow based ILC Therapeutics partners with University of St Andrews on Covid-19 drug
Lanarkshire business says Alfacyte could halt lung disease and prevent lasting damage in coronavirus patients
Scientists at ILC believe Alfacyte could be more effective than other drugs in preventing Covid-19 induced acute respiratory distress syndrome (ARDS).
They say it could reduce the need for many patients to be on a ventilator and could limit both short and long-term damage to lungs.
ILC, based at BioCity, Glasgow, is working with Dr Catherine Adamson of St Andrews’ School of Biology on progressing Alfacyte to clinical trials. The drug is based on a new type of interferon, a defence-triggering protein in which Adamson has expertise.
ILC Therapeutics founder and chief scientific officer Professor William Stimson, formerly of the University of Strathclyde, said: “We are delighted to be working with the University of St Andrews to develop our research and work as quickly as possible to bring this potential treatment option to those who need it.
“Dr Adamson’s work in the field of virology is highly respected, and to have her backing in our research for Alfacyte is invaluable as we progress towards eventual clinical trials.”
Dr Adamson added: “I welcome the opportunity to work with ILC Therapeutics to carry out further research into the part interferons play in the innate immune system’s ability to fight Covid-19. By exploring this in more detail, we can hopefully move closer to having viable treatment options in the coming years.”